Cigarette smoking, genetic polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study by Nisa, Hoirun et al.
Nisa et al. BMC Cancer 2010, 10:274
http://www.biomedcentral.com/1471-2407/10/274
Open Access RESEARCH ARTICLE
© 2010 Nisa et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons At-
tribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Research article Cigarette smoking, genetic polymorphisms and 
colorectal cancer risk: the Fukuoka Colorectal 
Cancer Study
Hoirun Nisa*1, Suminori Kono1, Guang Yin1, Kengo Toyomura1, Jun Nagano1, Ryuichi Mibu2, Masao Tanaka2, 
Yoshihiro Kakeji3, Yoshihiko Maehara3, Takeshi Okamura4, Koji Ikejiri5, Kitaroh Futami6, Takafumi Maekawa6, 
Yohichi Yasunami7, Kenji Takenaka8, Hitoshi Ichimiya9 and Reiji Terasaka10
Abstract
Background: It is uncertain whether smoking is related to colorectal cancer risk. Cytochrome P-450 CYP1A1, 
glutathione-S-transferase (GST) and NAD(P)H:quinone oxidoreductase 1 (NQO1) are important enzymes in the 
metabolism of tobacco carcinogens, and functional genetic polymorphisms are known for these enzymes. We 
investigated the relation of cigarette smoking and related genetic polymorphisms to colorectal cancer risk, with special 
reference to the interaction between smoking and genetic polymorphism.
Methods: We used data from the Fukuoka Colorectal Cancer Study, a population-based case-control study, including 
685 cases and 778 controls who gave informed consent to genetic analysis. Interview was conducted to assess lifestyle 
factors, and DNA was extracted from buffy coat.
Results: In comparison with lifelong nonsmokers, the odds ratios (OR) of colorectal cancer for <400, 400-799 and ≥800 
cigarette-years were 0.65 (95% confidence interval [CI], 0.45-0.89), 1.16 (0.83-1.62) and 1.14 (0.73-1.77), respectively. A 
decreased risk associated with light smoking was observed only for colon cancer, and rectal cancer showed an 
increased risk among those with ≥400 cigarette-years (OR 1.60, 95% CI 1.04-2.45). None of the polymorphisms under 
study was singly associated with colorectal cancer risk. Of the gene-gene interactions studied, the composite 
genotype of CYP1A1*2A or CYP1A1*2C and GSTT1 polymorphisms was associated with a decreased risk of colorectal 
cancer, showing a nearly statistically significant (Pinteraction = 0.06) or significant interaction (Pinteraction = 0.02). The 
composite genotypes of these two polymorphisms, however, showed no measurable interaction with cigarette 
smoking in relation to colorectal cancer risk.
Conclusions: Cigarette smoking may be associated with increased risk of rectal cancer, but not of colon cancer. The 
observed interactions between CYP1A1 and GSTT1 polymorphisms warrant further confirmation.
Background
Both environmental and genetic factors are thought to
play an important role in colorectal carcinogenesis [1].
The role of genetic factors in the etiology of colorectal
cancer is estimated to be 35% in a twin study [2]. Recent
genome-wide association studies have identified several
novel single nucleotide polymorphisms (SNPs) associated
with colorectal cancer risk, suggesting the importance of
combination of low-penetrance genes [3]. Furthermore, it
is estimated that one SNP is involved in approximately
15% of colorectal cancer in European populations [4].
A large number of studies have consistently shown that
cigarette smoking is associated with increased risk of col-
orectal adenoma, a well-established precursor lesion of
colorectal cancer, as reviewed elsewhere [5,6]. The find-
ings on smoking and colorectal cancer are inconsistent,
however. While a recent meta-analysis reported a statisti-
cally significant 1.18-fold increase in the risk of colorectal
cancer associated with smoking [7], individual studies
showed a weak or null association between smoking and
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colorectal cancer [5,7]. For example, several studies sug-
gested a modest increase in the risk of colorectal cancer
associated with smoking [8-11], but other studies failed to
find such a positive association [12-14].
Tobacco smoke contains various types of carcinogens
such as polycyclic aromatic hydrocarbons (P AHs), het -
erocyclic amines, aromatic amines and N-nitrosamines
which require metabolic activation and detoxification by
different enzymatic pathways, including cytochrome P-
450 (CYP), glutathione-S- transferases (GSTs) and
NAD(P)H:quinone oxidoreductase 1 (NQO1). CYP1A1 is
a phase I, predominantly extrahepatic, microsomal
enzyme involved in the bioactivation of PAHs including
benzo(a)pyrene. Two functional polymorphisms are
known in the CYP1A1 gene; one is 3698T>C substitution
(CYP1A1*2A, rs 4646903) creating an MspI restriction
site in the 3'-flanking region, and the other is 2454A>G
substitution (CYP1A1*2C, rs 1048943) resulting in an
amino acid change in exon 7 (Ile462Val) [15]. The
CYP1A1*2A and CYP1A1*2C alleles are putatively linked
to higher inducibility of the enzyme, and some studies
have suggested an increased risk of tobacco-related can-
cers associated with these variant alleles [15,16]. An
increased risk of in situ colorectal carcinoma associated
with CYP1A1*2A  was reported in a small case-control
study in Hawaii [17], but no association between
CYP1A1*2A and colorectal cancer was observed in sub-
sequent studies [18-20]. CYP1A1*2C  was unrelated to
colorectal cancer risk in these studies [17-20], but was
associated with an increased risk in another study [21].
GSTs are a superfamily of detoxification enzymes that
facilitate the inactivation of chemical carcinogens and
environmental toxic compounds [22]. GSTs consist of
several classes of genes, and GSTM1 and GSTT1 poly-
morphisms have been investigated most intensively in
relation to tobacco-related cancers [22]. The null geno-
types of these polymorphisms result in a complete loss of
enzyme function and t hus ma y be a t increased ris k of
tobacco-related cancers [22]. Results on GSTM1  and
GSTT1 polymorphisms in relation to colorectal cancer
are inconsistent as reviewed elsewhere [23,24]. The
GSTP1 gene also has a functional polymorphism, but this
polymorphism is unlikely to play an important role for
smoking-related cancers [25]. The NQO1 is involved in
detoxification through their two electron reduction to
hydroquinones, thereby inhibiting the DNA adduct for-
mation although NQO1 can act as pro-oxidant in certain
conditions [26]. The functional 609C>T polymorphism
(rs 1800566) causing amino acid change (Pro187Ser)
results in loss of NQO1 activity, and may increase suscep-
tibility to the risk of cancer, especially of tobacco-related
cancers [26]. A meta-analysis suggested an increased sus-
ceptibility to colorectal cancer as well as lung and bladder
cancers associated with NQO1 187Ser allele, although the
results from individual studies were heterogeneous [27].
Previously, several studies have addressed the interac-
tion between cigarette smoking and one or more of these
polymorphisms on colorectal cancer risk [19,20,28-33],
and some suggested an interaction between GSTT1 or
GSTM1 null genotype and cigarette smoking [28,30] and
between CYP1A1*2A or CYP1A1*2C and cigarette smok-
ing [19]. Few studies have addressed the gene-gene inter-
action between phase I and II enzymes in relation to
colorectal carcinogenesis [20,21,34]. In the present study,
we examined the relation of CYP1A1, GSTM1, GSTT1
and NQO1 polymorphisms as well as of cigarette smok-
ing to colorectal cancer risk in the Fukuoka Colorectal
Cancer Study, a community-based case-control study
[35], focusing on the interaction with cigarette smoking
and gene-gene interaction. This is the first study regard-
ing combined genotypes of phase I and II enzymes and
colorectal cancer risk in Japan.
Methods
The Fukuoka Colorectal Cancer Study is a case-control
study of incident cases and community controls in Fuku-
oka City and three adjacent areas. Details of methodolog-
ical issues have been described elsewhere [35]. The study
protocol was approved by the ethics committees of the
Kyushu University, Faculty of Medical Sciences and of all
except two of the participating hospitals. The two hospi-
tals had no ethics committees at the time of survey, and
approval was obtained from the director of each hospital.
Subjects
Cases were a consecutive series of patients with histologi-
cally confirmed incident colorectal adenocarcinoma who
were admitted to one of the participating hospitals (two
university hospitals and six affiliated hospitals) for surgi-
cal treatment during the period September 2000 to
December 2003. Eligible cases were Japanese men and
women aged 20 to 74 years at time of diagnosis; lived in
the study area; had no prior history of partial or total
removal of the colorectum, familial adenomatous polypo-
sis, or inflammatory bowel disease; and were mentally
competent to give informed consent and to complete the
interview. Of the total 1,053 eligible cases, 840 (80%)
cases participated in the interview, and 685 gave
informed consent for the genotyping.
Controls were randomly selected from the study area
by frequency-matching with respect to gender and 10-
year age group. Eligibility criteria for controls were the
same as described for the cases except that they had no
prior diagnosis of colorectal cancer. A total of 1,500 per-
sons were selected as control candidates by a two-stage
random sampling, using residential registry. They wereNisa et al. BMC Cancer 2010, 10:274
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invited to participate in the study by mail. Of these, 833
persons participated in the survey, and 778 gave an
informed consent for the genotyping. The participation
rate for the interview was calculated as 60% (833 of
1,382), after exclusion of 118 persons for the following
reasons: death (n = 7), migration from the study area (n =
22), undelivered mail (n = 44), mental incompetence (n =
19), history of partial or total removal of the colorectum
(n = 21) and diagnosis of colorectal cancer after the sur-
vey (n = 5).
Interview
Research nurses interviewed cases and controls in person
regarding smoking, alcohol intake, physical activity and
other factors using a uniform questionnaire. Interviews
for cases were conducted in hospital during admission,
and those for controls were conducted mostly at public
community centers or collaborating clinics. The referent
time for cases was the date of the onset of symptoms or
the screening, and that for controls was the time of inter-
view. Detailed information on smoking history was ascer-
tained by asking individuals firstly whether they had ever
smoked cigarettes daily for one year or longer. Age of
starting smoking and that of quitting smoking (for past
smokers) were ascertained, along with years of smoking
and numbers of cigarettes smoked per day for each
decade of age from the second to eighth decade. Cumula-
tive exposure to cigarette smoking until the beginning of
the previous decade of age was expressed by cigarette-
years, the number of cigarettes smoked per day multi-
plied by years of smoking, and classified into 0, 1-399,
400-799 and >800 cigarette-years.
Alcohol consumption at the time of five years prior to
the referent time was elicited. The amount of alcohol was
expressed in the conventional unit; one go (180 mL) of
sake, one large bottle (633 mL) of beer and half a go (90
mL) of shochu were each expressed as one unit; and one
drink (30 mL) of whisky or brandy and one glass (100 mL)
of wine were each converted to a half unit. Questions on
physical activities elicited type of job (sedentary or stand-
ing work, work with walking, labor walk, hard labor work
and no job), activities in commuting and housework,
together with leisure-time activities at the time five years
previously. As described in detail previously [36], leisure-
time physical activity (including activities in commuting
and housework) was expressed as a sum of metabolic
equivalents (MET) multiplied by hours of weekly partici-
pation in each activity.
Height (cm), recent body weight and body weight at the
time 10 years before were elicited. Body mass index (kg/
m2) 10 years earlier was used because the current body
mass index was unrelated to risk [36]. Body weight 10
years earlier was not ascertained from 2 cases and 10 con-
trols and was substituted with the current body weight.
Genotyping
DNA was extracted from the buffy coat by using a com-
mercial kit (Qiagen GmbH, Hilden, Germany), and geno-
typing was performed using the PCR-RFLP or PCR
method. The PCR was performed in a reaction mixture of
10 μL containing approximately 50-150 ng/μL. Genotyp-
ing for the CYP1A1*2A polymorphism was analyzed by
PCR-RFLP using primers 5'-TAGGA GTCTT GTCTC
ATGCC T-3' (sense) and 5'-CAGTG AAGAG GTGTA
GCCGC T-3' (anti-sense) [17]. The PCR product of 340
bp was digested with MspI, resulting in fragments of 200
and 140 bp for the CYP1A1*2A allele. The CYP1A1*2C
polymorphism was determined by the PCR-RFLP
method using primers 5'-GAACT GCCAC TTCAG
CTGTC T-3' (sense) and 5'-GAAAG ACCTC CCAGC
GGTCA-3' (anti-sense) [37]. The PCR product of 187 bp
was cleaved into three fragments (120, 48 and 19 bp) in
the presence of the CYP1A1*2C allele, and otherwise into
two fragments (139 and 48 bp). GSTM1 and GSTT1 poly-
morphisms were determined by the multiplex PCR
method using primers for GSTM1, GSTT1 and albumin
as described elsewhere [38]. Genotyping for NQO1
Pro187Ser was performed as described earlier [39], using
primers 5'-TCTCC TCATC CTGTA CCTCT-3' (sense)
and 5'-TCCTC AGAGT GGCAT TCTGC-3' (anti-sense).
The PCR product of 230 bp was digested with HinfI,
resulting in fragments of 195 and 35 bp for the 187Pro
allele, and in fragments of 151, 44 and 35 bp for the
187Ser allele.
Statistical analysis
Associations of cigarette smoking and genetic polymor-
phisms with colorectal cancer were examined in terms of
odds ratio (OR) and 95% confidence interval (CI) which
were obtained from a logistic regression analysis. The
multivariate models always included indicator variables
for 5-year age class (starting with the lowest class of <50
years), sex, residence area (Fukuoka City or the adjacent
areas), body mass index 10 years ago (<22.5, 22.5-24.9,
25.0-27.4 or ≥27.5 kg/m2), smoking (0, 1-399, 400-799 or
≥800 cigarettes-years), alcohol intake (0, 0.1-0.9, 1.0-1.9
or ≥2.0 units/day), type of job (sedentary, moderate or
hard), leisure-time physical activity (0, 1-15.9 or ≥16
MET-hours/week) and parental history of colorectal can-
cer.
Gene-gene and gene-environment (smoking) interac-
tions were statistically evaluated based on the likelihood
test, comparing the model including a term or terms for
interaction and the model without. Deviation from the
Hardy-Weinberg equilibrium was evaluated by chi-
square test with 1 degree of freedom. Statistical signifi-
cance was declared if a two-sided P-value was less than
0.05. Statistical analyses were carried out using SAS ver-
sion 9.2 (SAS Institute, Cary, NC).Nisa et al. BMC Cancer 2010, 10:274
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Results
Table 1 shows the association between cigarette smoking
and colorectal cancer risk. Adjustment for the covariates
did not markedly change the results. As compared with
lifelong nonsmokers, men and women with a light expo-
sure to cigarette smoking (1-399 cigarette-years) showed
a moderate decrease in the OR of colorectal cancer. The
decreases in the OR in both sexes combined and in
women were statistically significant. The ORs for higher
categories of smoking were slightly greater than unity in
both men and women, but the increases were not statisti-
cally significant. In men and women combined, the mul-
tivariate-adjusted ORs for past and current smokers as
compared with lifelong nonsmokers were 0.90 (95% CI
0.66-1.24) and 0.80 (95% CI 0.58-1.05), respectively.
There was no clear association between cumulative years
of smoking and colorectal cancer; the multivariate-
adjusted ORs for 0, 1-14, 15-29 and ≥30 years of smoking
were 1.00 (referent), 0.73 (0.51-1.05), 0.92 (0.65-1.29) and
1.02 (0.69-1.49), respectively. Cases of colon and rectal
cancer numbered 384 and 290, respectively; 11 cases had
both colon and rectal cancers. The multivariate-adjusted
ORs of colon cancer for 0, 1-399, 400-799 and 800 ciga-
rette-years were 1.00 (referent), 0.49 (95% CI 0.32-0.73),
0.89 (0.60-1.33) and 1.02 (0.62-1.69), respectively, while
the corresponding values for rectal cancer were 1.00 (ref-
erent), 0.92 (0.60-1.42), 1.72 (1.10-2.66) and 1.23 (0.66-
2.26), respectively. The OR of rectal cancer for the high-
est two categories combined was 1.60 (95% CI 1.04-2.45).
None of the five polymorphisms showed a measurable
association with the risk of colorectal cancer, nor did the
composite genotype of GSTM1  and  GSTT1  (Table 2).
Each polymorphism was not associated with smoking
history (cigarette-years) in either men or women among
controls (data not shown). Frequencies of CYP1A1*2A
allele were 0.363 in cases and 0.372 in controls, and fre-
quencies of CYP1A1*2C allele were 0.221 in cases and
0.230 in controls. Frequencies of the 187Ser allele of
NQO1 polymorphism were 0.376 in cases and 0.385 in
controls. Genotype distributions of these three polymor-
phisms were in accordance with the Hardy-Weinberg
equilibrium within each cases and controls (all P >0.05).
CYP1A1*2A  and  CYP1A1*2C  polymorphisms were in
complete linkage disequilibrium.
There was no material interaction between cigarette
smoking and each polymorphism on colorectal cancer
risk (Table 3). Repeated analyses for men and for colon
and rectal cancers did not show any measurable interac-
tion between smoking and genotype.
We further examined gene-gene interactions for the
combination of CYP1A1 and GST polymorphisms (Table
4) and CYP1A1 and NQO1 polymorphisms (Table 5). The
combination of CYP1A1*2A or CYP1A1*2C and GSTT1
polymorphisms showed a nearly statistically significant
or significant interaction. The composite genotype of
GSTT1 non-null and CYP1A1*2A or CYP1A1*2C allele
was associated with a decreased risk of colorectal cancer
(Table 4). There was no measurable interaction between
Table 1: Risk of colorectal cancer according to cigarette smoking
Number (%)
Cigarette-years Cases Controls OR (95% CI)* OR (95% CI)†
Both sexes
0 299 (43.6) 326 (41.9) 1.00 (referent) 1.00 (referent)
1-399 117 (17.1) 201 (25.8) 0.68 (0.50-0.94) 0.65 (0.47-0.89)
400-799 195 (28.5) 180 (23.1) 1.21 (0.88-1.68) 1.16 (0.83-1.62)
≥800 74 (10.8) 71 (9.1) 1.21 (0.79-1.86) 1.14 (0.73-1.77)
Men
0 80 (18.8) 92 (18.8) 1.00 (referent) 1.00 (referent)
1-399 94 (22.1) 158 (32.2) 0.73 (0.49-1.09) 0.69 (0.46-1.04)
400-799 182 (42.7) 171 (34.9) 1.24 (0.85-1.81) 1.15 (0.78-1.71)
≥800 70 (16.4) 69 (14.1) 1.16 (0.72-1.87) 1.05 (0.64-1.71)
Women
0 219 (84.6) 234 (81.3) 1.00 (referent) 1.00 (referent)
1-399 23 (8.9) 43 (14.9) 0.55 (0.32-0.95) 0.48 (0.27-0.86)
≥400 17 (6.6) 11 (3.8) 1.59 (0.72-3.51) 1.54 (0.67-3.55)
* Adjusted for sex, age, and residence area.
† Adjusted for sex, age, residence area, alcohol consumption, body mass index, type of job, leisure-time physical activity and parental 
colorectal cancer.Nisa et al. BMC Cancer 2010, 10:274
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CYP1A1 and NQO1 polymorphisms in relation to col-
orectal cancer risk (Table 5). Decreased risks for the com-
bination of CYP1A1 variant allele and GSTT1 non-null
genotype were observed only in men; the multivariate-
adjusted ORs were 0.62 (95% CI 0.42-0.90) for the combi-
nation of CYP1A1*2A allele and GSTT1 non-null geno-
type (Pinteraction = 0.04) and 0.63 (95% CI 0.43-0.91) for
that of CYP1A1*2C allele and GSTT1 non-null genotype
(Pinteraction = 0.07).
Cigarette smoking showed no effect modification on
associations with composite genotypes of CYP1A1 and
GST  or  NQO1  polymorphisms. For example, the
decreased risk among individuals harboring CYP1A1*2A
or CYP1A1*2C allele and GSTT1 non-null genotype was
o b s e r v e d  r e g a r d l e s s  o f  e x p o s u r e  t o  s m o k i n g .  I n  o t h e r
words, high exposure to smoking was consistently related
to an increased risk of colorectal cancer across different
composite genotypes (see additional file 1).
Discussion
Many studies have addressed the association between
cigarette smoking and colorectal cancer risk, and their
findings are highly variable although an 18% increase in
colorectal cancer risk was estimated for ever-smokers
versus never-smokers in a recent meta-analysis [7]. The
variable results may be due to differences in study
method, statistical power and ethnicity. The association
may differ by sex or location of colorectal cancer. In fact,
prospective studies showed higher risk estimates than
case-control studies in the meta-analysis [7]. Further-
more, while an increased risk associated with smoking
was observed in both men and women, the positive asso-
ciation with smoking was more evident for rectal cancer
than for colon cancer [7]. The present finding adds to evi-
dence that cigarette smoking is associated with increased
risk of rectal cancer. It was unexpected that individuals
with an exposure of 1-399 cigarette-years had a decreased
risk of colorectal cancer. This decrease was observed for
Table 2: Risk of colorectal cancer in relation to selected genetic polymorphisms
Number (%)
Genotype Cases, n = 685 Controls, n = 778 OR (95% CI)*
CYP1A1*2A
0† 283 (41.3) 305 (39.2) 1.00 (referent)
1 307 (44.8) 368 (47.3) 0.90 (0.72-1.13)
2 95 (13.9) 105 (13.5) 0.97 (0.70-1.35)
CYP1A1*2C
0† 418 (61.0) 461 (59.3) 1.00 (referent)
1 231 (33.7) 276 (35.5) 0.94 (0.75-1.17)
2 36 (5.3) 41 (5.3) 1.00 (0.62-1.62)
GSTM1
Non-null 328 (47.9) 356 (45.8) 1.00 (referent)
Null 357 (52.1) 422 (54.2) 0.90 (0.73-1.11)
GSTT1
Non-null 347 (50.7) 435 (55.9) 1.00 (referent)
Null 338 (49.3) 343 (44.1) 1.20 (0.97-1.48)
GSTM1 + GSTT1
Non-null 502 (73.3) 589 (75.7) 1.00 (referent)
Null 183 (26.7) 189 (24.3) 1.09 (0.86-1.39)
NQO1 Pro187Ser‡
Pro/Pro 259 (37.9) 282 (36.3) 1.00 (referent)
Pro/Ser 336 (49.1) 392 (50.5) 0.94 (0.75-1.18)
Ser/Ser 89 (13.0) 103 (13.3) 0.97 (0.69-1.35)
* Adjusted for sex, age, residence area, cigarette smoking, alcohol consumption, body mass index, type of job, leisure-time physical activity 
and parental colorectal cancer.
† Number of the variant allele.
‡ One case and one control were excluded because of undetermined genotype.Nisa et al. BMC Cancer 2010, 10:274
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colon cancer but not for rectal cancer, and was more
marked in women. Previously, some case-control studies
also suggested that smoking was associated with a
decreased risk of distal colon cancer in Caucasians [40]
and of colon cancer in Japanese [41,42]. We have no clear
explanation to the decreased risk of colon cancer associ-
ated with light smoking although confounding remains a
possible explanation.
In agreement with the results from three studies [18-
20], the present study did not show an association of
either  CYP1A1*2A  or  CYP1A1*2C polymorphism with
c olo r ectal  ca nc e r  ris k.  An 8-f o ld incr eased ris k of  c ol-
orectal cancer among Japanese homozygotes of
CYP1A1*2A allele in Hawaii is probably a chance finding
due to small numbers (23 cases and 59 controls) [17]. Of
these previous studies, two examined the interaction
between CYP1A1 polymorphisms and smoking [19,20].
One study reported an increased risk of rectal cancer, but
not of colon cancer, among former and current smokers
who did not carry either CYP1A1*2A  or  CYP1A1*2C
allele [19], while the other study showed no interaction
between either of the CYP1A1 polymorphisms and smok-
ing on colorectal cancer risk [20].
The  GSTM1 and  GSTT1 polymorphisms were unre-
lated to colorectal cancer risk singly or in combination in
the present study. GSTM1 null genotype was associated
with a small, statistically significant increase in the risk of
colorectal cancer in some case-control studies [21,32],
but not in several other studies [20,28-31]. Likewise, the
previous findings on GSTT1 null genotype and colorectal
cancer are inconsistent. A meta-analysis based on 11
studies reported a small increase in colorectal cancer risk
associated with GSTT1 null genotype, but the results of
these studies were highly heterogeneous [24]. Most of the
previous studies found no increase in the risk of colorec-
tal cancer in individuals with the combined null genotype
of GSTM1 and GSTT1 [21,28,31]. On the other hand, a 5-
fold increased risk of colorectal cancer was reported for
simultaneous carriers of both GSTM1 and GSTT1 null
genotypes in a study of 144 cases and 329 healthy con-
Table 3: Effect modification of cigarette smoking on colorectal cancer risk associated with selected genetic 
polymorphisms
< 400 ≥ 400
Genotype n* OR (95% CI)† n* OR (95% CI)† P for interaction
CYP1A1*2A
0‡ 161/207 1.00 (referent) 122/98 1.76 (1.19-2.59) 0.14
≥1 255/320 1.04 (0.79-1.36) 147/153 1.30 (0.91-1.87)
CYP1A1*2C
0‡ 243/309 1.00 (referent) 175/152 1.58 (1.14-2.20) 0.30
≥1 173/218 1.03 (0.79-1.34) 94/99 1.28 (0.87-1.86)
GSTM1
Non-null 207/245 1.00 (referent) 121/111 1.38 (0.96-1.97) 0.68
Null 209/282 0.88 (0.67-1.14) 148/140 1.33 (0.94-1.87)
GSTT1
Non-null 211/301 1.00 (referent) 136/134 1.51 (1.08-2.13) 0.60
Null 205/226 1.24 (0.95-1.61) 133/117 1.67 (1.18-2.37)
GSTM1+GSTT1
Non-null 304/407 1.00 (referent) 198/182 1.53 (1.14-2.07) 0.29
Null 112/120 1.20 (0.89-1.63) 71/69 1.41 (0.94-2.11)
NQO1 Pro187Ser§
Pro/Pro 157/189 1.00 (referent) 102/93 1.41 (0.95-2.09) 0.89
Pro/Ser + Ser/
Ser
259/338 0.94 (0.72-1.24) 166/157 1.37 (0.96-1.94)
* Numbers of cases/controls.
† Adjusted for sex, age, residence area, alcohol consumption, body mass index, type of job, leisure-time physical activity and parental 
colorectal cancer.
‡ Number of the variant allele.
§ One case and one control were excluded because of undetermined genotype.Nisa et al. BMC Cancer 2010, 10:274
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trols in Spain [43]. In that study [43], GSTM1 and GSTT1
null genotypes were also statistically significantly associ-
ated with 1.9-fold and 3.6-fold increased risks, respec-
tively. Frequencies of GSTM1 and GSTT1 null genotypes
vary with different populations [22], but the difference in
genotype distribution does not seem to explain the differ-
ent results. The combined null genotype of GSTM1 and
GSTT1 accounted for 24% among controls in the present
study and for 7% in the Spanish study [43]. The statistical
power was obviously greater in the present study than in
the Spanish study.
At least six case-control studies have examined the
relation between NQO1  Pro187Ser polymorphism and
colorectal cancer [27], and only one study, which
included 371 cases and 415 healthy controls in the Neth-
erlands, showed a statistically significant increase in the
risk associated with the variant 187Ser allele [44]. On the
other hand, homozygotes of the NQO1 187Ser allele was
Table 4: Combinations of CYP1A1 and GST polymorphisms and colorectal cancer risk
Number (%)
Combination of genotypes Cases Controls OR (95% CI)* P for 
interaction
CYP1A1*2A GSTM1
0† Non-null 122 (17.8) 135 (17.4) 1.00 (referent)
≥1 Non-null 206 (30.1) 221 (28.4) 1.02 (0.74-1.40) 0.34
0 Null 161 (23.5) 170 (21.9) 1.01 (0.72-1.42)
≥1 Null 196 (28.6) 252 (32.4) 0.84 (0.61-1.15)
CYP1A1*2A GSTT1
0† Non-null 147 (21.5) 158 (20.3) 1.00 (referent)
≥1 Non-null 200 (29.2) 277 (35.6) 0.75 (0.56-1.01) 0.06
0 Null 136 (19.9) 147 (18.9) 0.93 (0.67-1.30)
≥1 Null 202 (29.5) 196 (25.2) 1.07 (0.79-1.45)
CYP1A1*2A GSTT1 + GSTM1
0† Non-null 203 (29.6) 222 (28.5) 1.00 (referent)
≥1 Non-null 299 (43.6) 367 (47.2) 0.88 (0.69-1.13) 0.51
0 Null 80 (11.7) 83 (10.7) 0.99 (0.68-1.43)
≥1 Null 103 (15.0) 106 (13.6) 1.03 (0.73-1.44)
CYP1A1*2C GSTM1
0† Non-null 187 (27.3) 207 (26.6) 1.00 (referent)
≥1 Non-null 141 (20.6) 149 (19.2) 1.06 (0.78-1.45) 0.29
0 Null 231 (33.7) 254 (32.6) 0.98 (0.75-1.29)
≥1 Null 126 (18.4) 168 (21.6) 0.83 (0.60-1.13)
CYP1A1*2C GSTT1
0† Non-null 214 (31.2) 239 (30.7) 1.00 (referent)
≥1 Non-null 133 (19.4) 196 (25.2) 0.76 (0.56-1.01) 0.02
0 Null 204 (29.8) 222 (28.5) 0.98 (0.75-1.29)
≥1 Null 134 (19.6) 121 (15.6) 1.23 (0.90-1.69)
CYP1A1*2C GSTT1 + GSTM1
0† Non-null 300 (43.8) 337 (43.3) 1.00 (referent)
≥1 Non-null 202 (29.5) 252 (32.4) 0.90 (0.70-1.15) 0.39
0 Null 118 (17.2) 124 (15.9) 1.00 (0.74-1.36)
≥1 Null 65 (9.5) 65 (8.4) 1.13 (0.77-1.66)
* Adjusted for sex, age, residence area, cigarette smoking, alcohol consumption, body mass index, type of job, leisure-time physical activity 
and parental colorectal cancer.
† Number of the variant allele.Nisa et al. BMC Cancer 2010, 10:274
http://www.biomedcentral.com/1471-2407/10/274
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associated with a 2-fold increase in the prevalence odds
of colorectal adenomas in the United States [34]. In that
study [34], individuals having both CYP1A1*2C  and
NQO1  187Ser variant alleles showed a significantly
increased risk, particularly among heavy smokers. The
present findings showed neither an increased risk of col-
orectal cancer in relation to the composite of CYP1A1
variant allele and NQO1 187Ser alleles nor an interaction
between the composite genotypes and smoking.
A unique finding in the present study is that
CYP1A1*2A or CYP1A1*2C allele was associated with a
decreased risk only in individuals with GSTT1 non-null
genotype. Interpretation of these findings is rather diffi-
cult, particularly because the association was confined to
men. Available evidence suggests at least a secondary role
of the CYP1A1  polymorphisms for increased risks of
smoking-related cancers although the association
between these polymorphisms and enzyme activity or
property remains controversial [16]. Two case-controls
studies of smaller sizes previously examined the com-
bined effect of CYP1A1*2C and either GSTM1 [20,21] or
GSTT1  [20] null genotype, showing no interaction
between the two. The present findings on CYP1A1 and
GSTT1 polymorphisms in combination may be due to
chance, and need to be consolidated in further studies.
The use of community controls, the large number of
subjects, and ethnic homogeneity of the study population
were strengths of the present study. The statistical powers
were fairly large except for CYP1A1*2C polymorphism.
The powers of detecting an OR of 1.5 for variant homozy-
gotes compared with wild homozygotes (two-sided α =
0.05) were 0.71 for CYP1A1*2A, 0.42 for CYP1A1*2C and
0.69 for NQO1, and the corresponding values for null ver-
sus non-null genotype were 0.96 for GSTM1 and 0.93 for
GSTT1. There were several limitations to be discussed.
The participation in the interview was not as high in the
controls (60%) as in the cases (80%). We had no informa-
tion as to the difference between participant and non-
participant controls with respect to smoking history. The
overall participation for genotyping was rather low (65%
in cases and 56% in controls). Although older persons and
women were less likely to give consent for the genotyp-
ing, there was no difference between those who gave con-
sent and those who did not in terms of smoking,
residence area, and alcohol use [45]. A retrospective
assessment of cumulative exposure to cigarette smoking
is subject to inaccuracy, and may have been biased
because interviewers had known case-control status.
Lifestyle factors were assessed for different time periods
in the past for ease of recalling. This may have caused
inaccuracy to different extents for the covariates, leaving
different magnitudes of residual confounding. It is known
that GSTM1 and GSTT1 genes contain nonsynonymous
SNPs which may modify the enzyme activity [46], but
these SNPs seem to be of little relevance in Asians as well
as Caucasians [47]. Finally, although cases with familial
adenomatous polyposis were not included, other heredi-
tary colorectal cancers were not specifically ascertained
in the present study. However, in the analysis excluding
16 cases and 40 controls aged <40 years, the results were
essentially the same as those described above.
Conclusions
The present study showed a moderately decreased risk of
colorectal cancer, especially of colon cancer, in individu-
als with a light exposure to cigarette-smoking. A high
Table 5: Combinations of CYP1A1 and NQO1 polymorphisms and colorectal cancer risk
Number (%)
Combination of genotypes Cases Controls OR (95% CI)* P for 
interaction
CYP1A1*2A NQO1 Pro187Ser†
0‡ Pro/Pro 126 (18.4) 118 (15.2) 1.00 (referent)
≥1 Pro/Pro 133 (19.4) 164 (21.1) 0.78 (0.55-1.10) 0.22
0 Pro/Ser + Ser/Ser 157 (23.0) 187 (24.1) 0.81 (0.58-1.14)
≥1 Pro/Ser + Ser/Ser 268 (39.2) 308 (39.6) 0.83 (0.61-1.13)
CYP1A1*2C NQO1 Pro187Ser†
0‡ Pro/Pro 162 (23.7) 176 (22.7) 1.00 (referent)
≥1 Pro/Pro 97 (14.2) 106 (23.6) 1.04 (0.73-1.48) 0.53
0 Pro/Ser + Ser/Ser 256 (37.4) 285 (36.7) 1.00 (0.76-1.32)
≥1 Pro/Ser + Ser/Ser 169 (24.7) 210 (27.0) 0.90 (0.67-1.22)
* Adjusted for sex, age, residence area, cigarette smoking, alcohol consumption, body mass index, type of job, leisure-time physical activity 
and parental colorectal cancer.
† One case and one control were excluded because of undetermined genotype.
‡ Number of the variant allele.Nisa et al. BMC Cancer 2010, 10:274
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exposure to cigarette smoking was associated with an
increased risk of rectal cancer. None of the genetic poly-
morphisms relevant to the metabolism of tobacco carcin-
ogens showed a measurable association with the risk of
colorectal cancer. The observed interactions between
CYP1A1  and  GSTT1  polymorphisms warrant further
investigation.
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